
Objective To critically reassess low-dose radiotherapy (LDRT) in patients with osteoarthritis (OA) across the full translational pathway, from biological rationale to clinical efficacy and the requirements for definitive evaluation. Methods This multidisciplinary narrative review appraised mechanistic, preclinical and clinical evidence for LDRT in OA, with particular emphasis on the translational relevance of experimental models and on randomized evidence, especially sham-controlled trials. Recent technical consensus, safety assessments and OA trial-methodology literature were also considered. Results Preclinical studies support context-dependent immunomodulatory effects of LDRT involving endothelial–leukocyte interactions, immune-cell activation and joint-tissue crosstalk, but much of this evidence derives from reductionist or inflammatory models rather than chronic human OA. OA-specific experimental evidence remains limited. Clinically, two sham-controlled trials using 6 × 1 Gy were negative, whereas more recent studies using 6 × 0.5 Gy have reported positive signals that remain preliminary or methodologically limited. No responder phenotype has been validated. A definitive evaluation should therefore integrate clinically meaningful pain and/or functional impairment despite optimized standard OA care, prospective evaluation of inflammatory or imaging-based enrichment, biological target-engagement measures, standardized radiation delivery, rigorous sham-controlled OA outcomes, long-term safety, and assessment of clinical and health-system feasibility. Conclusion There is a biological rationale for LDRT in OA, but current evidence remains insufficient to support routine use in patients with OA. Its future role should be defined through adequately powered, phenotype-informed sham-controlled trials conducted jointly by OA and radiation experts.
Objective We investigated attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy of human synovial fluid across different osteoarthritis (OA) stages (healthy, early OA, late OA). Specifically, we evaluated partial least squares discriminant analysis (PLS-DA) performance for classifying OA status and examined associations between total protein concentration and Amide I and II absorbance peaks. Design Synovial fluid of healthy (N = 12), early OA (N = 13), and late OA (N = 14) donors were analyzed using ATR-FTIR spectroscopy. A PLS-DA model classified the OA status. We used linear regression, adjusted for age and sex, to estimate associations between total protein content and Amide I and II absorbances. Group differences in spectral peaks were evaluated using a linear mixed model, similarly adjusted. Results Late OA samples showed absorbance (a.u. [95% CI]) differences compared with healthy and early OA at several peaks, including 1647 cm−1 (0.45 [0.18,0.71]), 1452 cm−1 (−0.28 [−0.44,−0.13]), 1400 cm−1 (−0.27 [−0.39,−0.15]), 1119 cm−1 (−0.58 [−0.72,−0.44]), 1079 cm−1 (−0.25 [−0.37,−0.13]), and 1039 cm−1 (−0.46 [−0.61,−0.31]). The PLS-DA achieved 95% overall accuracy in classifying healthy, early OA, and late OA samples. Total protein content positively associated with Amide I and II absorbances. Amide II showed positive group-level associations in healthy (β = 12.0 [5.4,18.6]) and early OA (β = 9.3 [−0.4,19.1]), but association attenuated in late OA (β = 1.7 [−4.1,7.6]). Conclusions ATR-FTIR spectra of synovial fluid are associated with OA status. The ability to differentiate healthy, early OA, and late OA samples demonstrates the potential of ATR-FTIR spectroscopy as a label-free method for assessing joint health without adding chemical compounds.